5 Stocks to Buy According to Matthew Hulsizer’s PEAK6 Capital Management

In this article, we discuss 5 stocks to buy according to Matthew Hulsizer’s PEAK6 Capital Management. If you want to read our detailed analysis of Hulsizer’s history, investment philosophy, and hedge fund performance, go directly to 10 Stocks to Buy According to Matthew Hulsizer’s PEAK6 Capital Management.

5. Moderna, Inc. (NASDAQ:MRNA)

PEAK6 Capital Management’s Stake Value: $49,282,000
Percentage of PEAK6 Capital Management’s Portfolio: 0.1%
Number of Hedge Fund Holders: 41

Moderna, Inc. (NASDAQ:MRNA) is a company that works on developing transformational therapeutics based on messenger ribonucleic acid (mRNA). Philippe Laffont’s Coatue Management is the biggest stakeholder of Moderna, Inc. (NASDAQ:MRNA), increasing its hold on the company by 62% in Q1, with 6.93 million shares worth almost $1.19 billion.

PEAK6 Capital Management elevated its position in Moderna, Inc. (NASDAQ:MRNA) by 6% in Q1 2022, holding 286,090 shares worth over $49.28 million. The stock accounted for 0.1% of the fund’s total 13F portfolio.

The number of hedge funds tracked by Insider Monkey owning stakes in Moderna, Inc. (NASDAQ:MRNA) stood at 41 in Q1 2022, declining from 43 in the previous quarter. The total value of these holdings is more than $3.80 billion, down from $3.89 billion in Q4 2021.

Piper Sandler analyst Edward Tenthoff trimmed his price target on Moderna, Inc. (NASDAQ:MRNA) from $348 to $214 on May 17, noting pipeline modifications that reflect current market realities, but reiterated an Overweight rating on the company.

Carillon Tower Advisers mentioned Moderna, Inc. (NASDAQ:MRNA) in its Q3 2021 investor letter. Here is what the fund said:

“Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The stock proved to be an impressive contributor once again in the quarter, as investors continue to evaluate the potential for future growth driven primarily by the firm’s revolutionary COVID-19 vaccine. Strong global demand for the vaccine may persist for the foreseeable future in order to maintain immunity as well as provide protection against any additional future variants. The potential for the firm’s mRNA technology to be used in a number of other use cases, specifically influenza, could also provide an additional tailwind for future growth.”